

Folkert J Van Kemenade

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4418930/publications.pdf>

Version: 2024-02-01

53
papers

2,438
citations

201674

27
h-index

197818

49
g-index

53
all docs

53
docs citations

53
times ranked

2624
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of <sc>DNA</sc> methylation analysis of <i><sc>ASCL1</sc>, <sc>LHX8</sc>, <sc>ST6GALNAC5</sc>, <sc>GHSR</sc>, <sc>ZIC1</sc></i> and <sc><i>SST</i></sc> for the triage of <sc>HPV</sc>-positive women: Results from a Dutch primary <sc>HPV</sc>-based screening cohort. <i>International Journal of Cancer</i> , 2022, 150, 440-449.	5.1	17
2	Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 60-68.	8.1	42
3	Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic. <i>PLoS ONE</i> , 2022, 17, e0270223.	2.5	0
4	Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1418-1425.	4.4	12
5	Risk of Gynecologic Cancer after Atypical Glandular Cells Found on Cervical Cytology: A Population-Based Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 743-750.	2.5	0
6	Histological interpretation of differentiated vulvar intraepithelial neoplasia (dVIN) remains challenging—observations from a bi-national ring-study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 305-315.	2.8	13
7	Nuclear factor- κ B is downregulated in vulvar squamous cell carcinoma (VSCC): Unravelling differentially expressed genes in VSCC through gene expression dataset analysis. <i>Oncology Letters</i> , 2021, 21, 381.	1.8	2
8	Evaluation of Immunohistochemical Markers, CK17 and SOX2, as Adjuncts to p53 for the Diagnosis of Differentiated Vulvar Intraepithelial Neoplasia (dVIN). <i>Pharmaceuticals</i> , 2021, 14, 324.	3.8	9
9	Cervical intraepithelial neoplasia and the risk of spontaneous preterm birth: A Dutch population-based cohort study with 45,259 pregnancy outcomes. <i>PLoS Medicine</i> , 2021, 18, e1003665.	8.4	13
10	Exploring Differentially Methylated Genes in Vulvar Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3580.	3.7	4
11	Finding the Optimal Age Cutoff for the UICC/AJCC TNM Staging System in Patients with Papillary or Follicular Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 1041-1049.	4.5	23
12	Barriers and Facilitators for Implementing a National Guideline to Foster the Responsible Use of Residual Biospecimens and Data in Health Research. <i>Biopreservation and Biobanking</i> , 2021, , .	1.0	1
13	Relationship of human papillomavirus with seborrheic keratosis of the female genital tract - a case-series and literature review. <i>Histology and Histopathology</i> , 2021, , 18357.	0.7	1
14	Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e457-e465.	3.6	9
15	Relevance of routine pathology review in cervical carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 301-307.	2.8	0
16	The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cutoff level on yield of screening. <i>International Journal of Cancer</i> , 2020, 147, 1098-1106.	5.1	29
17	Precursor lesions of vulvar squamous cell carcinoma — histology and biomarkers: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 147, 102866.	4.4	32
18	Expression of p16 and HPV E4 on biopsy samples and methylation of FAM19A4 and miR124-2 on cervical cytology samples in the classification of cervical squamous intraepithelial lesions. <i>Cancer Medicine</i> , 2020, 9, 2454-2461.	2.8	13

#	ARTICLE	IF	CITATIONS
19	Experience with HPV self-sampling and clinician-based sampling in women attending routine cervical screening in the Netherlands. <i>Preventive Medicine</i> , 2019, 125, 5-11.	3.4	48
20	Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients. <i>Thyroid</i> , 2019, 29, 1073-1079.	4.5	39
21	Cryo-Gel embedding compound for renal biopsy biobanking. <i>Scientific Reports</i> , 2019, 9, 15250.	3.3	4
22	Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study. <i>BMC Medicine</i> , 2019, 17, 228.	5.5	83
23	Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. <i>Lancet Oncology</i> , The, 2019, 20, 229-238.	10.7	129
24	Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples. <i>Clinical Cancer Research</i> , 2018, 24, 3456-3464.	7.0	55
25	Presence or Absence of Significant HPVE4 Expression in High-grade Anal Intraepithelial Neoplasia With p16/Ki-67 Positivity Indicates Distinct Patterns of Neoplasia. <i>American Journal of Surgical Pathology</i> , 2018, 42, 463-471.	3.7	8
26	A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2018, 267, 1148-1154.	4.2	101
27	Differentiated vulvar intraepithelial neoplasia (dVIN): the most helpful histological features and the utility of cytokeratins 13 and 17. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 739-747.	2.8	31
28	Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation. <i>Gynecologic Oncology</i> , 2018, 151, 311-318.	1.4	7
29	Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer. <i>Thyroid</i> , 2018, 28, 976-981.	4.5	55
30	Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women. <i>Modern Pathology</i> , 2017, 30, 1021-1031.	5.5	49
31	Good performance of p16/Ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN. <i>International Journal of Cancer</i> , 2017, 140, 423-430.	5.1	16
32	Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study. <i>BMJ: British Medical Journal</i> , 2017, 356, j504.	2.3	24
33	Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2922-2929.	3.6	15
34	Validation of the FAM19A4 / mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. <i>Gynecologic Oncology</i> , 2016, 141, 341-347.	1.4	80
35	p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. <i>Modern Pathology</i> , 2016, 29, 870-878.	5.5	43
36	FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women. <i>British Journal of Cancer</i> , 2016, 115, 579-587.	6.4	55

#	ARTICLE	IF	CITATIONS
37	Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. <i>BMJ, The</i> , 2016, 355, i4924.	6.0	86
38	Comparing the performance of <i>FAM19A4</i> methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study). <i>International Journal of Cancer</i> , 2016, 138, 992-1002.	5.1	60
39	The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples. <i>International Journal of Cancer</i> , 2016, 139, 691-699.	5.1	23
40	Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates. <i>Cancer Causes and Control</i> , 2016, 27, 15-25.	1.8	44
41	Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening. <i>International Journal of Cancer</i> , 2015, 136, 646-655.	5.1	59
42	Offering Self-Sampling to Non-Attendees of Organized Primary HPV Screening: When Do Harms Outweigh the Benefits?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 773-782.	2.5	42
43	When Is It Effective to Offer Self-Sampling to Non-Attendees' Response. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1296-1296.	2.5	1
44	Exploring the trend of increased cervical intraepithelial neoplasia detection rates in the Netherlands. <i>Journal of Medical Screening</i> , 2015, 22, 144-150.	2.3	10
45	Triaging HPV-positive women with normal cytology by p16/Ki67 dual-stained cytology testing: Baseline and longitudinal data. <i>International Journal of Cancer</i> , 2015, 136, 2361-2368.	5.1	61
46	Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing. <i>Cancer Prevention Research</i> , 2015, 8, 502-508.	1.5	24
47	Primary hrHPV DNA Testing in Cervical Cancer Screening: How to Manage Screen-Positive Women? A POBASCAM Trial Substudy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 55-63.	2.5	82
48	Next generation diagnostic molecular pathology: Critical appraisal of quality assurance in Europe. <i>Molecular Oncology</i> , 2014, 8, 830-839.	4.6	44
49	Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. <i>Lancet Oncology, The</i> , 2014, 15, 315-322.	10.7	147
50	Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. <i>Lancet Oncology, The</i> , 2012, 13, 78-88.	10.7	431
51	Chromosomal profiles of high-grade cervical intraepithelial neoplasia relate to duration of preceding high-risk human papillomavirus infection. <i>International Journal of Cancer</i> , 2012, 131, E579-85.	5.1	37
52	Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. <i>International Journal of Cancer</i> , 2012, 130, 602-610.	5.1	179
53	Trends in cervical cancer in the Netherlands until 2007: Has the bottom been reached?. <i>International Journal of Cancer</i> , 2011, 128, 2174-2181.	5.1	46